Why InterMune Inc. Shares Exploded Higher By More Than 170%

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of InterMune (NASDAQ: ITMN  ) , a biopharmaceutical company primarily focused on pulmonary and fibrotic diseases, skyrocketed by as much as 174% after a report of positive phase 3 results from its ASCEND trial involving pirfenidone (known as Esbriet in Europe) in idiopathic pulmonary fibrosis, or IPF.

So what: According to InterMune's trial results, pirfenidone met both its primary and secondary endpoints in the study. As InterMune noted, a 10% decline in forced vital capacity, or FVC, in an IPF patient is considered clinically meaningful. Just 16.5% of patients taking pirfenidone after 52 weeks had a 10% decline in FVC, or death, compared to 31.8% in the placebo group, demonstrating a nearly 48% reduction over the control arm for the pirfenidone intent-to-treat group. In terms of secondary endpoints, pirfendione "reduced by 27.5% the proportion of patients who experienced a decline in the [six-minute-walking-distance test] of 50 meters of greater." This is important as the test is a measure of exercise tolerance since the treatment was initiated. Overall, pirfenidone reduced the risk of death or disease progression by 43% relative to the control arm. InterMune plans to resubmit its drug for FDA approval in the third quarter.

Now what: Considering that pirfenidone received a complete FDA response letter rejection in 2010, it's surprising to see how strong the data was today. Obviously, nothing is a sure thing when it comes to the FDA, but the primary and secondary endpoint data looks pretty convincing regarding an eventual approval. Still, even with few IPF treatment pathways available, RBC Capital analyst Michael Yee pegged its peak sales at just $300 million to $500 million. With a market valuation of more than $3 billion at the time of writing, and generally weak sales of Esbriet in currently approved European countries, I believe investors may be wise to rethink their optimism.

InterMune has more than doubled today, but even it may struggle to keep up with this top stock in 2014
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.


Read/Post Comments (1) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On February 25, 2014, at 10:41 PM, A2Matty wrote:

    Sean, I'm usually a skeptic as well, but these results were huge. I am sitting on nearly a 200% gain and I'm not selling (normally I would have been out mid-morning). What is not widely discussed here is that there are almost no treatments for fibrotic conditions. If approved, I think the IPF market will be the tip of the iceberg. There are hundreds of conditions that could be improved with its use...cirrhosis comes to mind. I'm no expert, but if I'm a large pharma company with a bunch of cash and a patent cliff/drought (pfe comes to mind), I'd be thinking acquisition!

Add your comment.

DocumentId: 2853468, ~/Articles/ArticleHandler.aspx, 4/16/2014 1:04:12 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement